A French Prospective, Non-interventional Research ( NIR) of Nivolumab in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After a Platinum-based Therapy
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ProNiHN
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results of effectiveness and quality of life for patients and their caregivers , presented at the 48th European Society for Medical Oncology Congress
- 12 Oct 2023 According to Bristol Myers Squibb media release, data from this study has been selected for ESMO 2023.
- 13 Sep 2022 Interim results (n=454) reporting follow-up outcomes and Quality of Life data presented at the 47th European Society for Medical Oncology Congress